Home » Newsletters » BioWorld Science

BioWorld Science

July 6, 2011

View Archived Issues

Preclinical and phase I data show LY-2409021 lowers glucose

Preclinical and clinical phase I and II data reported on antidiabetes agent MK-0893

Scripps Research Institute describes first potent lysophospholipid S1P4 receptor antagonists

GSK discloses new lysophospholipid S1P1 receptor agonists

Chimerix and BARDA reach agreement regarding sole-source contract for smallpox antiviral

Almirall launches Sativex in Germany for treatment of spasticity due to MS

Resverlogix's RVX-297 shows promise in model of multiple sclerosis

Boehringer Ingelheim claims new chemokine CCR2 receptor antagonists

New tachykinin NK3 receptor antagonists designed by Roche

Novel serine/threonine-protein kinase Chk1 inhibitors patented

Lundbeck presents new phosphodiesterase 10A inhibitors

Merck KGaA synthesizes new sphingosine kinase 1 inhibitors

Amgen and UCB join with NASA to test sclerostin-targeted antibody onboard space shuttle Atlantis

GSK receives approvals in Japan for Rotarix and Lamictal

Scancell's SCIB-2 cancer vaccine shows encouraging preclinical results

Sorrento Therapeutics is granted second phase I NIAID grant for MRSA program

Urigen and FDA set next steps for URG-101 study in interstitial cystitis

Chugai receives Japanese approval for additional indication of Pegasys/Copegus combination

Once-monthly minodronic acid formulation approved in Japan

BioLineRx enrolls first subject in phase I BL-1021 trial for neuropathic pain

FDA grants orphan drug status to INNO-206 in soft tissue sarcomas

FDA approves Archimedes Pharma's Lazanda for breakthrough cancer pain

Rib-X Pharmaceuticals and Sanofi enter collaboration to develop new classes of antibiotics

Nuvo Research receives FDA clearance to begin clinical testing of lidocaine spray

RESprotect reacquires North American rights to RP-101

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Gene therapies aim for the big goal of edits in vivo
BioWorld Science
The field of gene therapy is experiencing major advances driven by precise editing technologies, such as base and prime editing, and by the design of increasingly...